Keith McCain, PharmD, DABAT 

Associate Professor

Department of Pharmacy Practice
Phone: (501) 686-6161
Fax: (501) 296-1451
Office: Education II Bldg 6/134E
Email: mccainkeith@uams.edu

Education & Training

Doctor of Pharmacy, University of Arkansas for Medical Sciences (1996-2000)
Pre-pharmacy studies, Henderson State University (1993-1996)
General undergraduate studies, University of Central Arkansas (1992-1993)

Teaching Responsibilities

PhPr 6764  Experience – Specialty Pharmacy Practice, Toxicology. (Preceptor)
PhSc 5152   Toxicology. Clinical toxicology and management of the poisoned patient. (Lecturer)
PhPr 4454  Dispensing. Concepts in parenteral sterile products and admixture. (Lecturer)
PhPr 4454  Dispensing. Aseptic technique validation. (Lab Instructor)
PhSc 3414   Pharmaceutics I. Parenteral -Sterile Products (Lecturer)
PhPr 3422   Career Orientation & Communication. (Small Group Facilitator)

Clinical Practice

Clinical Toxicology

Research & Scholarly Interests

Novel psychoactive substances

Honors & Awards

  • 2012 Inducted to Rho Chi, Beta Iota chapter
  • 2011 Diplomate of the American Board of Applied Toxicology
  • 2011 Inaugural Jonathan J. Wolfe and Donna M. Wolfe Annual Endowed Award for Faculty Excellence
  • 2011 Cited as an AACP Teacher of the Year, American Association of Colleges of Pharmacy
  • 2006-2007 American Board of Applied Toxicology training program
  • 2005-2006 American Board of Applied Toxicology training program
  • 2000 The SmithKline Beecham Pharmaceuticals Award for Superior Achievement in Patient Care, UAMS College of Pharmacy

Memberships

  • American Board of Applied Toxicology
  • American Academy of Clinical Toxicology
  • American Association of Poison Control Centers
  • Arkansas Pharmacists Association
  • Arkansas Association of Health-System Pharmacists
  • National Home Infusion Association
  • Rho Chi Society – The Academic Honor Society in Pharmacy

Curriculum Vitae

Publications

Forensic investigation of K2, Spice, and “bath salt” commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds.
Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH.
Forensic Sci Int. 2013 Dec 10;233(1-3):416-22. doi: 10.1016/j.forsciint.2013.10.002. Epub 2013 Oct 14.

Not simply synthetic tetrahydrocannabinol.
Fantegrossi WE, McCain KR, Moran JH, Hoffman RS. J Pediatr. 2013 Dec;163(6):1797-8. doi: 10.1016/j.jpeds.2013.09.017. Epub 2013 Oct 13.

Targeted metabolomic approach for assessing human synthetic cannabinoid exposure and pharmacology. Patton AL, Seely KA, Chimalakonda KC, Tran JP, Trass M, Miranda A, Fantegrossi WE, Kennedy PD, Dobrowolski P, Radominska-Pandya A, McCain KR, James LP, Endres GW, Moran JH. Anal Chem. 2013 Oct 1;85(19):9390-9. doi: 10.1021/ac4024704. Epub 2013 Sep 12.

K2 toxicity: fatal case of psychiatric complications following AM2201 exposure.
Patton AL, Chimalakonda KC, Moran CL, McCain KR, Radominska-Pandya A, James LP, Kokes C, Moran JH. J Forensic Sci. 2013 Nov;58(6):1676-80. doi: 10.1111/1556-4029.12216. Epub 2013 Jul 3.

Comparison of the effects of energy drink versus caffeine supplementation on indices of 24-hour ambulatory blood pressure.
Franks AM, Schmidt JM, McCain KR, Fraer M.
Ann Pharmacother. 2012 Feb;46(2):192-9. doi: 10.1345/aph.1Q555. Epub 2012 Jan 31.

Publications